

# Subject index

## A

- $\alpha$ -scorpion toxin 18
- 1321N1 cells 75, 76–79, 81, 86–88
- acetylcholine 33, 110–111
  - neuromuscular junction 222, 224–226, 231–232
  - neuron–glia interactions 196
- actin/HSP70/sugar kinases 114–115
- action potentials 150–152, 153–154, 213, 215
- adenosine
  - astrocytes 214, 236
  - communication mechanisms 2–3
  - ectonucleotidases 123
  - Müller cells 196–197, 199–201, 203
  - myelination 22, 148, 151, 154–155, 160
  - neuron–glia interactions 229–230, 249
  - neurotrophins 181, 183, 186, 189–191
  - Schwann cells 162, 163–165, 167–173, 222, 224
- adenosine triphosphate (ATP)
  - astrocyte–neuron interactions 208–221
  - astrocytes 73–90, 91, 93–101, 105, 109–111, 143–144
  - communication mechanisms 1–4
  - ectonucleotidases 113, 117–119, 122, 128–130
  - microglia 264–274, 277–279
  - myelination 21, 22, 148–150, 152–156, 158–161
  - neurological pain 264–274
  - neuron–glia interactions 193–194, 198–200, 202–206, 227, 229–232, 236, 249–250
  - neuron–microglia interactions 253–261, 277–280
  - purinergic signalling 26–53
    - retina 193–194, 198–200, 202–206
    - Schwann cells 162–180
    - transport mechanisms 28, 76, 277
- adenyl purines 74–75
- Akt signalling 133, 135, 138, 186, 189–190
- alkaline phosphatases 118–119, 120
- allodynia 269, 273
- Alzheimer's disease 9, 10, 108
- amacrine cells 203
- AMPA 211, 218, 220
- anion maxi channels 88
- antibodies 56–57
- AOPCP 199
- apyrase 193, 197, 206
- aryl diisothiocyanates 63, 64
- astrocyte–astrocyte communication 91
- astrocytes
  - adenosine 236
  - adenyl purines 74–75
  - Ca<sup>2+</sup> signalling 209–216, 219–220
  - Ca<sup>2+</sup> wave propagation 208, 209–211, 214, 219
  - cell cycle 134
  - cell–cell communication 91, 93–95, 100–101
  - cell–cell interactions 132–138, 143–145
  - communication mechanisms 1, 3
  - desensitization 218
  - ectonucleotidases 122–123, 129
  - extracellular accumulation 74–75, 76–78
  - gliosis 95–98, 100–101, 104, 131
  - glutamate regulation 239–240
  - hypothalamus 238–243
  - injury repair 7–9
  - myelination 153–154, 156
  - neuron–glia interactions 194, 206, 208–221, 232, 238–243, 245
  - pathophysiological roles 91–101, 104–105

plasticity 275–276  
 protein kinases 131, 133–136, 138,  
 139–140, 144–145  
 purinergic signalling 43, 48, 54, 71, 107  
 reactive astrocytosis 145–146  
 regulated release of ATP 76  
 retina 194, 206  
 roles and functions 6–9  
 subcellular sources of nucleotides 80–82  
 thrombin-activated 78–79, 86–87  
 uridine nucleotides and sugars 73–90,  
 91–92, 94, 100  
 ATP *see* adenosine triphosphate

**B**

$\beta$ -galactosidase 23  
 Ba<sup>2+</sup> 200  
 bafilomycin 82, 85  
 BAPTA 89, 230  
 BBB *see* blood–brain barrier  
 BDNF *see* brain-derived neurotrophic factor  
 benzoyl benzoyl ATP (Bz-ATP) 94–95, 97,  
 137, 143–144, 164–165, 255–256  
 blood–brain barrier (BBB) 50, 70–71, 118  
 bone resorption 40–41  
 botulinum toxin 158–159  
 brain trauma 100–101, 105, 144  
 brain-derived neurotrophic factor  
 (BDNF) 181, 183  
 8-bromo-cAMP 179  
 Bz-ATP *see* benzoyl benzoyl ATP

**C**

Ca<sup>2+</sup>-regulated exocytosis 85–86  
 Ca<sup>2+</sup> signalling  
 astrocytes 76, 84, 87–89, 209–216,  
 219–220  
 extracellular signal regulated protein  
 kinases 146–147  
 microglia 263, 266  
 Müller cells 193–202, 204, 206–207  
 myelination 149–152, 159  
 neuromuscular junction 222, 223–225,  
 227, 230  
 neuron–glia interactions 233–235, 245  
 purinergic signalling 56, 92, 96–97, 98  
 thrombin 277  
 Ca<sup>2+</sup> wave propagation 1  
 astrocytes 85, 91–95, 100–101, 209–211,  
 214, 219

ectonucleotidases 113, 123  
 Müller cells 205  
 neuron–glia interactions 224–225  
 purinergic signalling 40  
 cAMP  
 myelination 161  
 Schwann cells 163, 165, 171–172,  
 175–176, 179  
 cAMP-responsive element binding protein  
 (CREB) 151–152, 159  
 cancer 42–43  
 cartilaginous fishes 15, 16  
 Cd<sup>2+</sup> 199  
 cell adhesion molecules 3  
 cell cycle 37–38, 48, 134  
 cell–cell communication 3  
 astrocytes 91, 93–95, 100–101  
 growth factors 280  
 purinergic signalling 138–139  
 central nervous system (CNS)  
 glial cells 5–13  
 myelination 15–20, 148–161  
 neuron–microglia interactions 253–262  
 purinergic signalling 92, 107, 111  
 cephalopods 15, 16  
 CFTR *see* cystic fibrosis transmembrane  
 regulator  
 CGRP receptors 222  
 chemotaxis 265  
 cholinergic amacrine cells 203  
 chromaffin granules 76, 85  
 chronic myelogenous leukaemia 139  
 ciliary neurotrophic factor (CNTF) 159  
 clopidogrel 52–53  
 clostridial toxins 85  
 CNS *see* central nervous system  
 CNTF *see* ciliary neurotrophic factor  
 connexin 43 channels 85, 88  
 constitutive exocytosis 82  
 COX2 *see* cyclooxygenase 2  
 CREB *see* cAMP-responsive element  
 binding protein  
 cyclooxygenase 2 (COX2) 96–97, 105  
 cystic fibrosis transmembrane regulator  
 (CFTR) 88

**D**

D-serine 246, 248–250  
 danger signals 256–257  
 DCs *see* dendritic cells

- dendritic cells (DCs) 49–50  
 DHK *see* dihydrokainate  
 1,4-di-(phenylthioureido) butanes 63  
 diadenosine polyphosphates 118  
 4,5-diarylimidazolines 63  
 differentiation 146, 157, 162, 172, 176  
 dihydrokainate (DHK) 240, 242  
 diketopiperazines (DKPs) 64–65, 69  
 DKPs *see* diketopiperazines  
 dorsal root ganglia (DRG)  
   ectonucleotidases 115  
   myelination 19, 148, 149–150, 153–156  
   neuron–glia interactions 254  
   neuropathic pain 268, 273  
   plasticity 275  
   Schwann cells 163, 165, 175–177  
 DPCPX 199  
 DRG *see* dorsal root ganglia  
 dynorphin 71
- E**
- E-NPP *see* ectonucleotide pyrophosphatase/  
 phosphodiesterase  
 E-NTPDase *see* ectonucleoside triphosphate  
 diphosphohydrolase  
 ECS *see* extracellular space  
 ecto-5'-nucleotidase 119, 120, 122, 125, 145  
 ecto-nucleoside diphosphokinases  
 (NDPK) 77, 82  
 ectonucleoside triphosphate  
   diphosphohydrolase (NTPDase)  
   family 42, 113–117, 120–122, 124–125,  
   128–130, 179–180, 260–261, 279  
 ectonucleotidases 69, 113–130  
   alkaline phosphatases 118–119, 120  
   astrocytes 122–123, 129, 214  
   ecto-5'-nucleotidase 119, 120, 122, 125,  
   145  
   extracellular nucleotides 113, 119, 129  
   microglia 123, 129  
   neurogenesis 124  
   neuron–glia interactions 260–261, 279  
   nicotinamide adenine dinucleotide  
   metabolism 119–120  
   NPP family 117–118, 120, 125, 128  
   NTPDase family 42, 113–117, 120–122,  
   124–125, 128–130, 179–180,  
   260–261, 279  
   purinergic signalling 120–122  
   retina 199  
   Schwann cells 175, 179–180  
   simple cellular systems 121–122  
   synaptic interactions 122–123  
   vascular control 123–124  
 ectonucleotide pyrophosphatase/  
 phosphodiesterase (NPP) family  
 117–118, 120, 125, 128  
 EGF *see* epidermal growth factor  
 embryonic development 38, 40  
 endocrine secretion 34–35  
 endoplasmic reticulum (ER) 80–81  
 enkephalin 71  
 ensheathing glial cells 15, 19, 21–22  
 enteric ganglia 115  
 enteric glial cells 43  
 enteric nervous system 6  
 ependymal cells 6  
 epidermal growth factor (EGF) 182,  
 184–185, 186–187, 191  
 EPSCs *see* excitatory post-synaptic currents  
 EPSP *see* excitatory post-synaptic potential  
 ER *see* endoplasmic reticulum  
 ERK1/2 *see* extracellular-regulated kinases  
 excitatory post-synaptic currents  
 (EPSCs) 241, 243  
 excitatory post-synaptic potential  
 (EPSP) 213, 215  
 exocrine secretion 34–35  
 extracellular nucleotides 113, 119, 129  
 extracellular signal regulated protein  
 kinases 146–147  
 extracellular space (ECS) 240, 243–245  
 extracellular-regulated kinases (ERK1/2)  
   cell–cell interactions 131, 133–138, 144,  
   146–147  
   growth factors 162, 165–173, 175–180  
   microglia 266–267  
   myelination 151–152  
   neurotrophins 186, 189–190  
   pathophysiological roles 91, 96–97  
   purinergic signalling 49, 51, 52
- F**
- fast purinergic signalling 26, 33–37  
 FGF2 *see* fibroblast growth factor 2  
 fibroblast growth factor 2 (FGF2)  
   astrocytes 131, 132–135, 137–138,  
   143–144  
   purinergic signalling 44, 51  
 forskolin 176, 179

**G**

- G protein-coupled inwardly rectifying K<sup>+</sup> channels (GIRKs) 200, 202
- G protein-coupled receptor (GPCR) ligands 181–192
- GABA 193–194, 196, 229–230, 240–243, 245–246
- ganglion cells 197–200, 202–205  
*see also* dorsal root ganglia
- GFAP *see* glial fibrillary acidic protein
- GIRKs *see* G protein-coupled inwardly rectifying K<sup>+</sup> channels
- glia–axon interactions 139, 149
- glia–glia connections 131, 139
- glia–neuron signalling 196–200
- glia–synapse interactions 225, 226–227
- glial cells  
  ensheathing 15, 19, 21–22  
  enteric 6, 43  
  injury repair 7–9, 12  
  non-spiking interneurons 57  
  perisynaptic 3, 7  
  purinergic signalling 43–45, 91–106  
  radial 7  
  roles and functions 5–13, 22  
  synapse formation 5, 7  
*see also* astrocytes; microglia; myelin; oligodendrocytes; Schwann cells
- glial fibrillary acidic protein (GFAP) 44, 54, 95, 132, 144–145, 218, 225–226, 275–276
- gliosis 95–98, 100, 104, 131
- glutamate 110–111  
  astrocyte–neuron interactions 208–221  
  neuron–glia interactions 193–196, 206–207, 231, 239–246, 249–250, 275
- glycine 217
- glycogen synthase kinase (GSK) 49, 133–138, 147
- glycosylphosphatidyl inositol (GPI) anchors 118, 255–256
- gnathostoma 15, 16
- Golgi apparatus 80–82, 86–89, 191
- GPCR *see* G protein-coupled receptor
- GPI *see* glycosylphosphatidyl inositol
- growth factors 3, 124  
  myelination 148  
  neuron–glia interactions 280–281

- neurotrophins 181–192  
  purinergic signalling 162–180  
  Schwann cells 162–180  
  *see also* fibroblast growth factor 2
- GSK *see* glycogen synthase kinase
- guanine nucleotides 250

**H**

- hemichannels 84, 88
- heterosynaptic depression 229–230, 236, 242–243
- hippocampus 3, 52, 123–124, 183, 206, 211–214, 218, 220, 230–231
- hyperpolarization 193, 198
- hypothalamus 238–252

**I**

- IFN *see* interferons
- immune cells 41–42
- inflammatory astrogliosis 100–101
- inhibitory post-synaptic currents (IPSCs) 241, 243
- injury repair 7–9, 12
- inosine 176
- inositol phosphates 74, 92
- inositol-1,4,5-triphosphate (IP<sub>3</sub>) 209–210, 226, 267
- INS 37217 (Up<sub>4</sub>dC) 58, 59
- interferons 45
- interleukins 254, 256–257, 259–260, 263–268, 270
- internalization 109
- interneurons 57, 211, 229–231
- intracellular Ca<sup>2+</sup> waves *see* Ca<sup>2+</sup> waves
- invertebrates 15, 16, 19–20, 54
- ionotropic (P2X) receptors *see* purinergic signalling
- IP<sub>3</sub> *see* inositol-1,4,5-triphosphate
- IPSCs *see* inhibitory post-synaptic currents
- ischaemia 41, 100–101, 105, 130
- isoPPADS 64
- isoquinolines 63

**K**

- K<sup>+</sup> channels 200, 202, 214, 275

**L**

- leukaemia inhibitory factor (LIF) 153–154, 159

lipopolysaccharides (LPS) 98–99, 101, 105, 259–260  
 long-term depression (LTD) 230–231  
 long-term potentiation (LTP) 229  
 long-term purinergic signalling 37–40  
 LPA *see* lipophosphatidic acid  
 LPS *see* lipopolysaccharides  
 LTD *see* long-term depression  
 LTP *see* long-term potentiation  
 luciferase 255–258, 259–260  
 lyophosphatidic acid (LPA) 129

## M

MAPK *see* mitogen-activated protein kinase  
 membrane ruffling 265  
 metabotropic glutamate receptors  
 (mGluRs) 209, 212, 213–214, 240–243  
 metabotropic (P2Y) G protein-coupled  
 receptors *see* purinergic signalling  
 methanocarbo analogues 58, 59–63, 69  
 2-methylthio-ADP 94, 164–165, 177  
 Mg<sup>2+</sup> 213–214, 217–218  
 mGluRs *see* metabotropic glutamate  
 receptors  
 microglia 1  
 chemotaxis 265  
 cytokine release 265–268, 273–274  
 ectonucleotidases 123, 129  
 membrane ruffling 265  
 neurological pain 263–274  
 neuron–glia interactions 253–262,  
 277–279  
 pathophysiological roles 91, 98–99, 101,  
 104–105  
 plasticity 276  
 purinergic signalling 43, 48, 55, 107–108  
 roles and functions 6, 9–11  
 microglial response factor (MRF1) 45  
 mitogen-activated protein kinase  
 (MAPK) 44–45, 147  
 growth factors 162, 165–173  
 myelination 159  
 neurological pain 263, 265–266, 270  
 neurotrophins 186  
 mitogenic signalling 163, 167–170, 175–180  
 MPEP 230  
 MRF1 *see* microglial response factor  
 MS *see* multiple sclerosis  
 Müller cells 13, 43, 193  
 multiple sclerosis (MS) 9, 10

muscle fibres 3  
 myelination  
 action potentials 150–152, 153–154  
 adenosine triphosphate 148, 149–150,  
 152–156, 158–161  
 astrocytes 153–154, 156  
 axon firing 149–150, 152–154  
 cell development 17  
 cell types 19  
 developmental significance 155–156  
 ectonucleotidases 117, 128  
 evolutionary appearance 16–17, 19–20  
 glial cells 1, 4, 6  
 invertebrates 15, 16, 19–20  
 nerve impulses 148–161  
 oligodendrocytes 9, 15–24  
 purinergic signalling 148–161  
 requirements for myelination 17–18  
 Schwann cells 10–11, 15–24, 162,  
 163–167, 176

## N

N-cadherin 139  
 N9 cells 98–99  
 Na<sup>+</sup> channels 212  
 Na<sup>+</sup>/K<sup>+</sup> ATPase 177  
 NAD *see* nicotinamide adenine dinucleotide  
 NANC *see* non-adrenergic/non-cholinergic  
 NDPK *see* ecto-nucleoside diphosphokinases  
 NECA 196–197  
 nerve growth factor (NGF) 181, 182, 183  
 nerve impulses 148–161  
 nervous system *see* central nervous system;  
 enteric nervous system; peripheral  
 nervous system  
 neuregulin 22–23, 24, 162, 173  
 neurodegenerative diseases  
 neuron–glia interactions 250  
 neurotrophins 181  
 purinergic signalling 91, 95–96, 98,  
 100–101, 104–105, 108–109  
 neurogenesis 124  
 neuroinflammatory diseases 100–101,  
 103–104, 107–109  
 neurological pain 263–274  
 neuromuscular junction (NMJ) 222–232  
 neuron–glia interactions  
 astrocytes 131, 139, 232, 238–243, 245  
 Ca<sup>2+</sup> signalling 233–235, 245  
 Ca<sup>2+</sup> wave propagation 224–225

communication mechanisms 3–4, 12–13  
 growth factors 280–281  
 hypothalamus 238–252  
 microglia 253–262  
 neuromuscular junction 222–232  
 oligodendrocytes 237  
 plasticity 275  
 protein kinases 131  
 purinergic signalling 55, 193–207,  
 208–221  
 research implications 245–246  
 retina 193–207  
 Schwann cells 162, 222–228, 232  
 neuropsychiatric diseases 181  
 neurotrophins 3–4, 95, 101, 181–192  
 NGF *see* nerve growth factor  
 nicotinamide adenine dinucleotide  
 (NAD) 119–120  
 nitric oxide 34, 45, 225  
 NK-1 receptors 225  
 NMDA receptors 208, 212–216, 217–218,  
 220, 246, 249–251  
 (*N*)-methanocarbo analogues 58, 59–63, 69  
 NMJ *see* neuromuscular junction  
 nociceptive purinergic mechanosensory  
 transduction 35–37  
 nodes of Ranvier 9  
 non-adrenergic/non-cholinergic (NANC)  
 inhibitory neurotransmission 33–34  
 non-nucleotide antagonists 58, 63–66  
 non-spiking interneurons 57  
 noradrenaline 33, 110–111, 122  
 NPP *see* ectonucleotide pyrophosphatase/  
 phosphodiesterase  
 NTPDase *see* ectonucleoside triphosphate  
 diphosphohydrolase  
 nucleotide antagonists 58, 59–63

**O**

OECs *see* olfactory ensheathing glial cells  
 olfactory ensheathing glial cells (OECs) 6,  
 19, 22  
 oligodendrocyte progenitors (OPs) 92, 129,  
 148, 149, 152–154, 159–160  
 oligodendrocytes  
 ectonucleotidases 128–129  
 myelination 9, 15–24, 148, 149, 152–154,  
 159–160  
 neuron–glia interactions 237  
 neurotrophins 189–190

purinergic signalling 43, 91, 92  
 roles and functions 6, 9  
 OPs *see* oligodendrocyte progenitors  
 optic nerve 178  
 oxytocin 238–239, 249

**P**

P1/P2 purinoceptors *see* purinergic  
 signalling  
 p75 receptors 181, 183, 190–191  
 PACAP *see* pituitary adenylate cyclase  
 activating polypeptide  
 pain mechanisms 4, 263–274  
 PAMP *see* pathogen-associated molecular  
 pattern  
 parallel brain processing 236  
 paraventricular nucleus (PVN) 238–239  
 Parkinson's disease 108  
 pathogen-associated molecular pattern  
 (PAMP) 257  
 PDGF *see* platelet-derived growth factor  
 peptides 3  
 peripheral nervous system (PNS)  
 ectonucleotidases 115  
 glial cells 5–13  
 myelination 15–20, 148–161  
 purinergic signalling 107  
 perisynaptic glia 3, 7, 222–228  
 perisynaptic Schwann cells (PSCs) 222–228  
 pertussis toxin (PTX) 226, 265  
 phenol red 68–69, 137, 144  
 1,4-phenylendiisothiocyanates 64  
 phospholipases 92, 96  
 phosphotyrosine phosphatase (PTP) 185  
 PI3K/Akt pathway 186, 189–190  
 pituitary cells 251  
 pituitary adenylate cyclase activating  
 polypeptide (PACAP) 181, 183–185,  
 187  
 plasma membrane luciferase  
 (pmeLUC) 255–258, 259–260  
 plasminogen 264, 265  
 platelet aggregation 35  
 platelet-derived growth factor (PDGF) 162,  
 163–165, 170  
 pleiotrophins 95, 101  
 pmeLUC *see* plasma membrane luciferase  
 PNS *see* peripheral nervous system  
 PPADS 64, 96, 128, 209–211, 265, 269  
 presynaptic glia 149

- prolactin 49
- protein kinases 49, 51
- astrocytes 131, 133–136, 138, 139–140, 144–145
  - Ca<sup>2+</sup> signalling 146–147
  - microglia 266–267
  - myelination 151–152
  - neurotrophins 191
  - see also* mitogen-activated protein kinase
- protovertebrates 15, 16
- PSCs *see* perisynaptic Schwann cells
- PTP *see* phosphotyrosine phosphatase
- PTX *see* pertussis toxin
- purinergic signalling
- action potentials 150–152, 153–154
  - agonists 58–72
  - antagonists 58–72
  - antibodies 56–57
  - astrocyte–neuron interactions 208–221
  - astrocytes 91, 93–101, 104–105, 107, 131–138, 143–145
  - astrogliosis 95–98, 100–101, 104, 131
  - Ca<sup>2+</sup>-dependent cell–cell communication 91, 93–95, 100–101
  - cancer 42–43
  - cell cycle 37–38, 48
  - cell–cell interactions 138–139
  - characteristics 28–33
  - communication mechanisms 2–3
  - complexity 107–108
  - differentiation 51, 146, 157, 162, 172, 176
  - ectonucleotidases 116–117, 120–122
  - embryonic development 38, 40
  - exocrine and endocrine secretion 34–35
  - fast purinergic signalling 26, 33–37
  - glia–neuron signalling 196–200, 202, 208–221
  - glial cells 43–45, 91–106
  - growth factors 162–180
  - historical background 26–28
  - homology modelling 65
  - immune cells 41–42
  - inflammation 41–42
  - internalization 48, 109
  - ischaemia 41
  - microglia 91, 98–99, 101, 104–105, 107–108
  - mitogenic signalling 163, 167–170, 175–180
  - myelination 23–25, 148–161
  - nerve impulses 148–161
  - neuron–glia interactions 193–207, 208–221, 233, 249–250
  - neuron–microglia interactions 253–262, 277
  - neuropathic pain 268–270, 273
  - neurotransmission 223
  - nociceptive purinergic mechanosensory transduction 35–37
  - pathophysiology 91–106
  - physiology and pathophysiology 33–45
  - platelet aggregation 35
  - receptor structure 65
  - reperfusion injury 41
  - retina 193–207
  - ring constrained nucleotides 58, 59–63, 69
  - Schwann cells 162–180, 223–227
  - slow purinergic signalling 37–40
  - synapse–glia interactions 225, 226–227
  - therapeutics 139–140
  - vascular endothelial cell-mediated vasodilatation 35
  - wound healing 40–41
- PVN *see* paraventricular nucleus
- pyrazolidine-3,5-diones 63
- pyridoxal-5'-phosphates 64
- pyridyl isatogen 69
- pyrimidines 28–30, 38–39, 40–41, 58
- see also* uridine nucleotides
- Q**
- quinacrine staining 85
- R**
- radial glial cells 7
- Ras/Raf pathway 96–97, 169
- reactive astrocytosis 145–146
- reactive astrogliosis 95–98, 131
- reactive oxygen species (ROS) 260
- receptor tyrosine kinases (RTK) 181, 182–187, 189–190
- regulated exocytosis 76
- reperfusion injury 41
- retina 3, 18, 123, 193–207
- ROS *see* reactive oxygen species
- RTK *see* receptor tyrosine kinases
- S**
- Schwann cells
- ectonucleotidases 115
  - growth factors 162–180

injury repair 8, 12  
 mitogenic signalling 163, 167–170  
 myelination 10–11, 15–24, 148–156,  
     159–160, 162–167, 176  
 neuron–glia interactions 222–228, 232  
 neurotrophins 189–190  
 purinergic signalling 43, 162–180  
 roles and functions 6, 8, 11–12  
 sciatic nerve 173, 178  
 seventh nerve nucleus studies 105  
 slow inward currents (SICs) 212–214,  
     217–218  
 slow purinergic signalling 37–40  
 SNARE proteins 159, 219  
 SON *see* supraoptic nucleus  
 Src family of protein tyrosine kinases 191  
 stroke 104  
 substance P 222  
 subventricular zone (SVZ) 6–7, 124  
 sugar nucleotides 73–90, 91–92, 94, 100  
 supraoptic nucleus (SON) 238–252  
 suramin 60, 61, 63, 71, 94, 96, 111, 128,  
     193, 195–197, 203, 265  
 SVZ *see* subventricular zone  
*swiss cheese Drosophila* mutation 19, 22  
 synapse–glia interactions 225, 226–227  
 synapses 5, 7, 122–123, 149  
 synaptobrevin 2 85  
 synaptotagmin 2 158

**T**

taurine 246  
 tetrodotoxin (TTX) 18, 196, 197, 212,  
     230  
 thapsigargin 198  
 8-thiobutyl-ATP 130  
 thrombin 78–79, 86–87, 277  
 thrombospondin 139, 146  
 TNF *see* tumour necrosis factors  
 TNP-ATP *see* trinitrophenol ATP

transcriptional factors 91, 151–152, 265, 267  
 trinitrophenol ATP (TNP-ATP) 130, 269,  
     273  
 Trk *see* tyrosine kinase  
 trophic purinergic signalling 37–40  
 tumour necrosis factors (TNF) 257, 259,  
     262–266, 268, 270  
 tyrosine kinase (Trk) receptors 181,  
     183–187, 189–190

**U**

UDP *see* uridine nucleotides  
 Up<sub>4</sub>dC 58, 59  
 uridine nucleotides (UDP/UTP)  
     astrocytes 73–90  
     ectonucleotidases 119  
     myelination 160  
     pathophysiological roles 91–92, 94, 100  
     purinergic signalling 50, 52, 59, 62  
     receptors 72  
 UTP *see* uridine nucleotides

**V**

vascular control 123–124  
 vascular endothelial cell-mediated  
     vasodilatation 35  
 vasoactive intestinal polypeptide (VIP)  
     33–34  
 vasopressin 238–239, 249  
 VDACs *see* voltage dependent anion  
     channels  
 VIP *see* vasoactive intestinal polypeptide  
 voltage dependent anion channels (VDACs)  
     88

**W**

wortmannin 135  
 wound healing 40–41

